Navigation Links
Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
Date:11/3/2008

CALGARY, Nov. 3 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that it has achieved positive interim results in its Phase I and Phase II U.K. combination REOLYSIN(R) and paclitaxel/carboplatin clinical trials for patients with advanced cancers. The principal investigator for the trial is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

The results were presented at the International Society for Biological Therapy of Cancer (iSBTC) annual meeting on November 1, 2008. The meeting was held in San Diego, California from October 31 - November 2, 2008.

"The most striking finding," said George M. Gill, MD, Oncolytic's Senior VP of Clinical and Regulatory Affairs, "is that in nine evaluable late-stage head and neck cancer patients, eight of whom have refractory disease, four had durable partial responses and four others showed stable disease for periods of two, five plus, and eight cycles."

Four of the responding patients continue on study, while a fifth patient is too early to evaluate for response. These results appear to confirm preclinical evidence of synergy for REOLYSIN(R) and platinum/taxane combinations. A U.S. Phase 2 trial has now been opened in this patient population utilizing this regimen.

Fourteen patients have been treated to date in the Phase I and Phase II (REO 011) trials. The detailed results are summarized in the following table:

-------------------------------------------------------------------------

REOLYSIN

Primary Tumour Dose TCID(50) Cycles Best Response

-------------------------------------------------------------------------

Phase I patients

-------------------------------------------------------------------------

Melanoma 3x10(9) 2 PD

-------------------------------------------------------------------
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... (PRWEB) September 17, 2014 JH ... California showroom located in Irvine. JH Technologies, a ... imaging systems, recently announced an expanded partnership with Leica ... leading microscopes and image analysis solutions will be featured ... 2nd. The new showroom facility is located within ...
(Date:9/17/2014)... 17, 2014 Intarcia Therapeutics, Inc. ... a study of the cost and predictability of non-adherence ... Annual Meeting of the European Association for the ... Christian Frois , Ph.D., of Analysis Group, Inc. ... planned Intarcia-sponsored, retrospective studies to characterize the prevalence of ...
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... molecular diagnostics company pioneering the field of molecular cytology, ... chief operating officer. Mr. Hall joined Veracyte ... company,s commercial entry into endocrinology. Since 2012, he has ... well as managed care and billing functions. As chief ...
(Date:9/17/2014)... 17, 2014 Escape Alert, LLC . filed ... which will alert owners if their pet has escaped and enable ... implanted microchip in the pet’s body. This is the first ... pets have been around for many years, they are passive until ... to track a pet’s location or alert the owner that the ...
Breaking Biology Technology:JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 2Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 3
... by leading European authority on natural/ organic ... Oct. 6 /PRNewswire-FirstCall/ - Botaneco Specialty Ingredients,Inc. (Botaneco), ... that its second generation oleosome product, Hydresia(TM) G2, ... material, complying with,the standards for ecological and organic ...
... software and services company, today announced SPL for ... Documentum,s Documentum Compliance Manager (DCM) application. SPL ... solution and addresses the SPL Release 4 submission ... latest addition to Glemser,s family of pharmaceutical labeling ...
... contains many genes encoding proteins that are similar to those ... for only a small fraction the genome, and there are ... What are these sequences doing, and do we really need ... in Genome Research ( www.genome.org ), researchers have ...
Cached Biology Technology:Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2 2Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2 3Glemser Announces New Labeling Solution: SPL for DCM Addresses New SPL Release 4 Requirements 2Use it or lose it? Researchers investigate the dispensability of our DNA 2
(Date:9/17/2014)... MRSA and MSSA could be curbed by coating ... scaly surface of shark skin, according to research ... Resistance and Infection Control . , The study ... of human disease bacteria through touching, sneezes or ... of ridges formulated to resemble shark skin. The ...
(Date:9/16/2014)... (17 September, 2014)More than $100 trillion in cumulative ... annual carbon dioxide (CO2)a 40 percent reduction of ... if the world expands public transportation, walking and ... released by the University of California, Davis, and ... , Further, an estimated 1.4 million early ...
(Date:9/16/2014)... viruses that make us sick can take up residence ... sneeze, cough or other troublesome symptom, according to new ... Louis. , On average, healthy individuals carry about ... report online in BioMed Central Biology . The ... diversity of viruses in healthy people. , The ...
Breaking Biology News(10 mins):Sharks' skin has teeth in the fight against hospital superbugs 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3
... BETHLEHEM, PA, March 17, 2009 -- Lehigh University ... awarded a $1.8 million grant from the National ... and Other Communication Disorders for his research entitled ... grant will allow Burger to build upon the ...
... between food, nutrition science, and health outcomes have been ... individuals and populations is a new factor that enriches ... the rapidly emerging intersection of nutritional science and genomics ... issue of OMICS: A Journal of Integrative Biology ...
... papilloma virus (HPV)-infections can lead to cellular changes in ... cancer. Surgical treatment of these pre-stages gives an increased ... HPV-vaccine can prevent pre-stages of cervical cancer, it may ... Norwegian study has calculated the benefits of HPV-vaccination. ...
Cached Biology News:Lehigh researcher awarded $1.8 million NIH grant 2Lehigh researcher awarded $1.8 million NIH grant 3Nutrigenomics -- developing personalized diets for disease prevention -- part 2 just published in OMICS 2HPV vaccine may prevent preterm births 2
Human Apolipoprotein B100 Affinity Purified Polyclonal Ab ENTREZ GeneID: 338...
Mouse Ameloblastin Biotinylated Affinity Purified PAb ENTREZ GeneID: 11698...
Human SOST Affinity Purified Polyclonal Ab...
Homo sapiens CDC23 (cell division cycle 23, yeast, homolog),...
Biology Products: